Table 1.

Baseline participant characteristics^a

Characteristic	Participants (N = 39)
Demographic characteristics
Age (yrs)	65 [58, 75]
Female sex	10 (26%)
Black race	23 (59%)
White race	14 (36%)
Other race	2 (5%)
Hispanic ethnicity	6 (15%)
Comorbid medical conditions
Diabetes	26 (67%)
Congestive heart failure	16 (41%)
Coronary artery disease	17 (44%)
Hypertension	35 (90%)
Kidney failure cause
Diabetes	17 (44%)
Hypertension	16 (41%)
Glomerular disease	2 (5%)
Other	4 (10%)
Dialysis treatment characteristics
Dialysis vintage (yrs)	1.5 [1, 3]
Hemodialysis treatment time (mins)	229 [210, 249]
Postdialysis weight (kg)	88 [68, 102]
Interdialytic weight gain (kg)	2.0 [1.6, 3.0]
Predialysis systolic blood pressure (mmHg)	153 [136, 168]
Vascular access type
Fistula	29 (74%)
Graft	3 (8%)
Catheter	7 (18%)
Laboratory measures
Serum potassium (mEq/l)	4.5 [4.2, 4.9]
Serum magnesium (mg/dl)	2.0 [1.8, 2.2]
Serum corrected calcium (mg/dl)	8.8 [8.4, 9.2]
Serum albumin (g/dl)	4.0 [3.9, 4.3]
24-h urine volume (ml)	290 [110, 740]
Medications
ACE-inhibitor or ARB use	13 (33%)
Beta blocker use	27 (69%)
Calcium channel blocker use	21 (54%)
Loop diuretic use	22 (56%)
Vasodilator use	2 (5%)
Other antihypertensive use	8 (21%)
Patient-reported outcome measures
Inner EAR score	42 [38, 55]
Symptoms reported as severe or very severeb
Cramping	6 (15%)
Dizziness or lightheadedness	0 (0%)
Unusual tiredness	2 (5%)
Unusual weakness	2 (5%)
Chest pain	1 (3%)
New rash	0 (0%)
Nausea or upset stomach	0 (0%)
Vomiting	0 (0%)
Diarrhea	0 (0%)
Tinnitus	1 (3%)
Hearing change	0 (0%)
Numbness or tingling	2 (5%)

ACE, angiotensin converting enzyme; ARB, angiotensin receptor blocker; EAR, effectiveness of auditory rehabilitation.

^aValues are presented as number (%) or median [quartile 1, quartile 3].

^bSymptoms during hemodialysis in the last week reported by the participant as severe or very severe on a 5-point severity Likert scale.